(Q38119551)

29 August 2017

Approaches to immunosuppression in Behçet's disease (English)

1 reference

29 August 2017

0 references

1 reference

David Saadoun

4

0 references

Patrice Cacoub

object named as

Patrice Cacoub

series ordinal

3

0 references

Cloé Comarmond

series ordinal

1

object named as

Cloé Comarmond

1 reference

29 August 2017

2

Bertrand Wechsler

1 reference

29 August 2017

1 July 2013

1 reference

29 August 2017

1 reference

29 August 2017

5

1 reference

29 August 2017

7

1 reference

29 August 2017

743-754

1 reference

29 August 2017

1 reference

2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides

21 January 2018

1 reference

The International Criteria for Behçet's Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria.

21 January 2018

1 reference

Pathogenic gene responsible for the predisposition of Behçet's disease

21 January 2018

1 reference

HLA-B51/B5 and the risk of Behçet's disease: a systematic review and meta-analysis of case-control genetic association studies

21 January 2018

1 reference

Mortality in Behçet's disease.

21 January 2018

1 reference

EULAR recommendations for the management of Behçet disease

21 January 2018

1 reference

Management of Behçet disease: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Behçet disease.

21 January 2018

1 reference

Behçet disease: evolution of clinical manifestations.

21 January 2018

1 reference

A double-blind trial of colchicine in Behçet's syndrome

21 January 2018

1 reference

Thalidomide in the treatment of the mucocutaneous lesions of the Behçet syndrome. A randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

Use of thalidomide for severe recurrent aphthous stomatitis: a multicenter cohort analysis

21 January 2018

1 reference

Dapsone in Behçet's disease: a double-blind, placebo-controlled, cross-over study

21 January 2018

1 reference

A controlled trial of azathioprine in Behçet's syndrome

21 January 2018

1 reference

Anti-TNF agents for Behçet's disease: analysis of published data on 369 patients

21 January 2018

1 reference

High dose methotrexate for ocular lesions of Behçet's disease. Preliminary short-term results.

21 January 2018

1 reference

Infliximab for patients with neuro-Behcet's disease: case series and literature review.

21 January 2018

1 reference

Cerebral venous thrombosis in Behçet's disease: clinical study and long-term follow-up of 25 cases

21 January 2018

1 reference

Behçet's syndrome and the nervous system

21 January 2018

1 reference

Spectrum of cardiac lesions in Behçet disease: a series of 52 patients and review of the literature

21 January 2018

1 reference

Long-term outcome of arterial lesions in Behçet disease: a series of 101 patients

21 January 2018

1 reference

The long-term mortality and morbidity of Behçet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center

21 January 2018

1 reference

Azathioprine in severe uveitis of Behçet's disease

21 January 2018

1 reference

Effect of infliximab on sight-threatening panuveitis in Behçet's disease.

21 January 2018

1 reference

Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: an open-label trial

21 January 2018

1 reference

Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Behçet disease

21 January 2018

1 reference

Azathioprine in Behcet's syndrome: effects on long-term prognosis

21 January 2018

1 reference

Long-term efficacy and safety of low-dose interferon alpha2a therapy in severe uveitis associated with Behçet disease

21 January 2018

1 reference

Low-dose weekly methotrexate for progressive neuropsychiatric manifestations in Behcet's disease.

21 January 2018

1 reference

Mycophenolate mofetil is ineffective in the treatment of mucocutaneous Adamantiades-Behçet's disease

21 January 2018

1 reference

High-dose cyclophosphamide without stem cell rescue for the treatment of refractory Behcet's disease

21 January 2018

1 reference

Multiple pulmonary arterial aneurysms in Behçet's disease: clinical and radiologic remission after cyclophosphamide and corticosteroid therapy

21 January 2018

1 reference

CNS involvement occurs more frequently in patients with Behçet's disease under cyclosporin A (CSA) than under other medications--results of a retrospective analysis of 117 cases.

21 January 2018

1 reference

Central nervous system symptoms in patients with Behçet disease receiving cyclosporine therapy.

21 January 2018

1 reference

Interferon alfa-2a in the treatment of Behçet disease: a randomized placebo-controlled and double-blind study

21 January 2018

1 reference

Interferon alfa-2a in the treatment of Behçet's disease

21 January 2018

1 reference

The use of interferon alpha in Behçet disease: review of the literature

21 January 2018

1 reference

Anti-TNF-alpha therapy for sight threatening uveitis

21 January 2018

1 reference

Therapeutic use of infliximab in sight threatening uveitis: retrospective analysis of efficacy, safety, and limiting factors.

21 January 2018

1 reference

Cytomegalovirus colitis in a patient with Behcet's disease receiving tumor necrosis factor alpha inhibitory treatment.

21 January 2018

1 reference

Differential efficacy of human recombinant interferon-alpha2a on ocular and extraocular manifestations of Behçet disease: results of an open 4-center trial

21 January 2018

1 reference

Interferon-alpha--a new therapeutic option in refractory juvenile Behçet's disease with CNS involvement.

21 January 2018

1 reference

Adalimumab for sight-threatening uveitis in Behçet's disease.

21 January 2018

1 reference

Adalimumab treatment for life threatening pulmonary artery aneurysm in Behçet disease: a case report

21 January 2018

1 reference

Health- and vision-related quality of life in patients receiving infliximab therapy for Behcet uveitis

21 January 2018

1 reference

Infliximab effects compared to conventional therapy in the management of retinal vasculitis in Behçet disease

21 January 2018

1 reference

Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behçet disease

21 January 2018

1 reference

Effects of anti-TNF-alpha antibody infliximab in refractory entero-Behcet's disease

21 January 2018

1 reference

Safety and efficacy of infliximab therapy in active behcet's uveitis: an open-label trial

21 January 2018

1 reference

Multicenter study of infliximab for refractory uveoretinitis in Behçet disease

21 January 2018

1 reference

Resistant Behçet disease responsive to anakinra

21 January 2018

1 reference

Rituximab in intractable ocular lesions of Behcet's disease; randomized single-blind control study (pilot study).

21 January 2018

1 reference

Remission induction in Behçet's disease following lymphocyte depletion by the anti-CD52 antibody CAMPATH 1-H.

21 January 2018

1 reference

A double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Behçet's disease

21 January 2018

1 reference

Autologous haematopoietic stem cell transplantation for Behcet's disease with pulmonary involvement: analysis after 5 years of follow up.

21 January 2018

1 reference

Haematopoietic stem cell transplantation for vasculitis including Behcet's disease and polychondritis: a retrospective analysis of patients recorded in the European Bone Marrow Transplantation and European League Against Rheumatism databases and a r

21 January 2018

1 reference

Autologous hematopoietic stem-cell transplantation for Behçet's disease with pulmonary involvement

21 January 2018

1 reference

Autologous non-myeloablative haematopoietic stem cell transplantation for refractory systemic vasculitis

21 January 2018

1 reference

A double-blind trial of depot corticosteroids in Behçet's syndrome

21 January 2018

1 reference

Safety and effectiveness of interferon alpha-2a in treatment of patients with Behçet's uveitis refractory to conventional treatments

21 January 2018

1 reference

Behçet Disease-associated Uveitis Successfully Treated with Golimumab

21 January 2018

1 reference

Cerebral venous thrombosis in Behçet's disease

21 January 2018

1 reference

Immunosuppressants reduce venous thrombosis relapse in Behçet's disease

21 January 2018

1 reference

Tuberculosis and Legionella pneumophila pneumonia in a patient receiving anti-tumour necrosis factor-α (anti-TNF-α) treatment

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/IMT.13.66

1 reference

29 August 2017

1 reference

PubMed ID

23829625